Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines

Advances in Experimental Medicine and Biology

Volumn 431, Issue , 1998, Pages 661-665

  Van Moorsel, C J A ^a   Veerman, G ^a   Ruiz Van Haperen, V W T ^b   Bergman, A M ^a   Jensen, P B ^c   Sehested, M ^c   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CYTIDINE DERIVATIVE; CYTIDINE TRIPHOSPHATE; DEOXYCYTIDINE; GEMCITABINE; GUANOSINE TRIPHOSPHATE; NUCLEOTIDE; RIBONUCLEOTIDE; URIDINE TRIPHOSPHATE;

CANCER RESISTANCE; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; LUNG CARCINOMA; NUCLEOTIDE METABOLISM; OVARY CARCINOMA; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL LINE; TUMOR XENOGRAFT;

EID: 0031808363     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5381-6_128     Document Type: Conference Paper

References (15)

1. Braakhuis BJM, Ruiz van Haperen VWT, Boven E, Veerman G and Peters GJ: Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Sem Oncol 22 (suppl 11):42-45, 1995.
2. Van Moorsel CJA, Peters GJ and Pinedo HM: Gemcitabine: future prospects of single agent and combination studies. The Oncologist 2:127-134, 1997.
3. Heinemann V, Hertel LW, Grindey GB and Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difIuorodeoxycytidine and I-B-D-arabinofuranoxylcytosine. Cancer Res 48:4024-4031, 1988.
4. Ruiz van Haperen VWT and Peters GJ: New targets for pyrimidine antimetabolites in the treatment of solid tumours II: Deoxycytidine kinase. Pharm World & Science 26:104-112, 1994.
5. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluoro-deoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991.
6. Ruiz van Haperen VWT, Veerman G, Vermerken JB and Peters GJ: 2′,2′-Difluoro-deoxycytidine (Gemcitabine) incorporation into RNAand DNA of tumour cell lines. Biochem Pharmacol 46:762-766, 1993.
7. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewad R and Gandhi V: Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Sem Oncol 22 (suppl. 11):42-46, 1995.
8. Ruiz van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB and Peters GJ: Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochemical Pharmacology 48: 1327-1339, 1994.
9. Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM and Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2:521-530, 1996.
10. Gandhi V and Plunkett W: Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation ans cytotoxicity of arabinosyl nucleosides. Cancer Res 50: 3675-3680, 1990.
11. Heinemann V and Plunkett W: Inhibitory action of 2′,2′-difluorodeoxycytidine (dFdC) on cytidine 5′-triphosphate synthetase. Ann Oncol 3 (suppl. 1): 187 (abstr. 510), 1992.
12. White JC and Capizzi RL: A critical role for undine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-β-D-arabinofuranosylcytosine phosphorylation in human leukemia cells. Cancer Res 51: 2559-2565, 1991.
13. Shewach DS, Reynolds KK and Hertel LW: Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol 42: 518-524, 1992.
14. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Pinedo HM and Peters GJ: Regulatory effects of CTP and UTP on deoxycytidine kinase activity in solid tumor cell lines. Biochem Pharmacol 51:911-918, 1996).
15. Weber G: Biochemical strategy of cancer cells and the design of chemotherapy: GHA Clowes Memorial Lecture. Cancer Res 43: 3466-3492, 1983.